Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Sangamo Therapeutics Inc    SGMO

SANGAMO THERAPEUTICS INC

(SGMO)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Sangamo Announces Nature Biotechnology Publication of New Strategies for Optimizing the Specificity of Gene Editing Nucleases: Sangamo Therapeutics Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/14/2019 | 04:57pm EDT

2019 AUG 14 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Business Daily -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced the publication in Nature Biotechnology of a manuscript by Jeffrey Miller, Ph.D., and colleagues at Sangamo, describing two new strategies for optimizing the specificity of genome editing using zinc finger nucleases (ZFNs). The ability to engineer highly specific gene editing nucleases with little or no detectable activity at unintended genomic sequences is a key safety factor for therapeutic applications. The strategies entail engineering the two key functional regions within the ZFN structure, namely adjusting the binding affinity of the zinc finger array which recognizes DNA, and slowing the catalytic rate of the Fok1 cleavage domain. The two approaches, which are complementary, may be combined to enable near 100% on-target modification with no detectable off-targets. The manuscript, titled “Enhancing gene editing specificity by attenuating DNA cleavage kinetics,” was published online on July 29 and will appear in the August issue of Nature Biotechnology. “When attempting to improve the specificity of genome editing tools, on-target editing efficiency is often sacrificed,” said Edward Rebar, Ph.D., Chief Technology Officer, Sangamo. “With these new strategies, the high efficiency we have observed previously with ZFN-mediated genome editing was completely preserved, while off-target activity was reduced by approximately 1000-fold, to below the level of detectability. These results are important as we believe the capabilities they demonstrate will help ensure the safety of our genome editing tools when used in the clinic.”

In order to adjust the binding affinity of the zinc finger recognition domain, the authors substituted a discrete, positively charged residue in the zinc finger framework to eliminate a nonspecific contact with the negatively charged phosphate backbone of the DNA. By varying the number of fingers bearing this substitution, the authors showed in cellular studies that they could effectively tune ZFN affinity into an optimally specific range, with no loss of on-target efficiency.

In a related series of cellular studies, the authors screened single-amino acid substitutions in the Fok1 nuclease domain in order to identify those able to improve specificity by slowing down catalysis. The goal of the study was to observe whether mutations would provide more time for the ZFNs to selectively dissociate from off-target sites prior to a cleavage event, which would improve global specificity. These studies yielded single-residue substitutions that could increase specificity by more than 1000-fold.

In a final study detailed in the manuscript, Sangamo scientists applied these two strategies in a therapeutically relevant setting by designing ZFNs that targeted the endogenous TCR-alpha gene in T-cells. Treatment of these T-cells with optimized ZFNs resulted in a greater than 98% on-target knockout efficiency of the TCR-alpha gene with undetectable off-target activity at a median assay background level of 0.01%. Sangamo believes these engineered improvements to the specificity of its ZFN genome editing platform have the potential to enable the routine generation of designed nucleases capable of high efficiency editing with minimal or no detectable off-target activity.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Copyright © 2019 NewsRx LLC, Biotech Business Daily, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANGAMO THERAPEUTICS INC
08/07SANGAMO : 2Q Earnings Snapshot
AQ
08/07SANGAMO THERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITI..
AQ
08/07SANGAMO THERAPEUTICS, INC : Results of Operations and Financial Condition, Finan..
AQ
08/07SANGAMO THERAPEUTICS : Reports Second Quarter 2019 Financial Results
BU
08/06SANGAMO THERAPEUTICS : Announces Participation at Upcoming Investor Conferences
BU
07/31SANGAMO THERAPEUTICS : Appoints Gary H. Loeb as Executive Vice President and Gen..
BU
07/31SANGAMO THERAPEUTICS : Announces Second Quarter 2019 Conference Call and Webcast
BU
07/29SANGAMO THERAPEUTICS : Announces Nature Biotechnology Publication of New Strateg..
BU
07/08MDC, Sangamo Therapeutics rise; Apple, F5 Networks decline
AQ
07/08Sangamo Therapeutics Up 17%; Unveiled Updated Study Data
DJ
More news
Financials (USD)
Sales 2019 51,8 M
EBIT 2019 -159 M
Net income 2019 -153 M
Finance 2019 377 M
Yield 2019 -
P/E ratio 2019 -8,41x
P/E ratio 2020 -7,53x
EV / Sales2019 18,6x
EV / Sales2020 19,7x
Capitalization 1 342 M
Chart SANGAMO THERAPEUTICS INC
Duration : Period :
Sangamo Therapeutics Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANGAMO THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 21,60  $
Last Close Price 11,60  $
Spread / Highest target 193%
Spread / Average Target 86,2%
Spread / Lowest Target -5,17%
EPS Revisions
Managers
NameTitle
Alexander Macrae President, Chief Executive Officer & Director
Kathy Yi CFO, Principal Accounting Officer & Senior VP
Edward J. Rebar Chief Technology Officer & Senior Vice President
Edward R. Conner Chief Medical Officer & Senior Vice President
Adrian Woolfson Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANGAMO THERAPEUTICS INC-1.13%1 342
GILEAD SCIENCES2.49%81 192
VERTEX PHARMACEUTICALS12.90%48 089
REGENERON PHARMACEUTICALS-20.11%32 649
GENMAB28.62%13 270
NEUROCRINE BIOSCIENCES, INC.36.17%9 041